UPDATE: West Pharma (WST) Q1 EPS Tops Views; Reaffirms Guidance
(Updated - April 27, 2017 9:16 AM EDT)
(Update corrects Q1 EPS)
West Pharma (NYSE: WST) reported Q1 EPS of $0.81, better than the analyst estimate of $0.55. First-quarter 2017 reported-diluted EPS includes the impact of a tax benefit of $0.21. Revenue for the quarter came in at $387.7 million versus the consensus estimate of $380.42 million.
- Reported net sales of $387.7 million grew 7.1% over the prior-year quarter. Net sales at constant currency grew by 8.7%.
- First-quarter 2017 reported-diluted EPS was $0.81, compared to prior-year quarter\'s results of reported-diluted EPS of $0.30 and adjusted-diluted EPS of $0.53. First-quarter 2017 reported-diluted EPS includes the impact of a tax benefit of $0.21 associated with the adoption of guidance issued by the Financial Accounting Standards Board (FASB) regarding share-based payment transactions.
- Reaffirming full-year 2017 sales and raising reported-diluted EPS guidance. Full-year 2017 sales guidance is unchanged and is expected to be between $1.585 billion to $1.610 billion. Full-year 2017 reported-diluted EPS guidance is now expected to be between $2.66 and $2.78, compared to the prior range of $2.45 and $2.57, and reflects the previously-discussed adoption of FASB-issued guidance.
For earnings history and earnings-related data on West Pharma (WST) click here.